Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cerilliant
US Department of Justice
US Army
Colorcon
Moodys
McKesson
Fish and Richardson
AstraZeneca

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

« Back to Dashboard

Clinical Trials for Lamivudine And Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Summary
NCT00013520 Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
NCT00033163 A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 Control of hepatitis B virus (HBV) infection can be difficult in HIV infected people who have taken the antiviral lamivudine (3TC). These people may have HBV that has become resistant to 3TC. Adefovir dipivoxil (ADV) has shown promising anti-HBV activity in clinical trials; tenofovir disoproxil fumarate (TDF) is used to treat HIV and may also be effective against HBV. The purpose of this study is to find out if adding ADV or TDF to a highly active antiretroviral therapy (HAART) regimen that includes 3TC has an effect on HBV infection in patients coinfected with HIV and HBV. The tolerability and safety of these drugs will be examined.
NCT00039741 Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2/Phase 3 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed PENTA Foundation Phase 2/Phase 3 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lamivudine And Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Lamivudine And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 19
HIV 7
HIV-1 Infection 6
Chronic Hepatitis B 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lamivudine And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 31
Hepatitis 15
Hepatitis B 14
Acquired Immunodeficiency Syndrome 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lamivudine And Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Lamivudine And Tenofovir Disoproxil Fumarate
Location Trials
United States 213
Germany 25
China 16
Canada 16
Italy 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lamivudine And Tenofovir Disoproxil Fumarate
Location Trials
California 15
Illinois 13
Florida 13
New York 12
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lamivudine And Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Lamivudine And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 20
Phase 3 20
Phase 2/Phase 3 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lamivudine And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Completed 33
Recruiting 13
Active, not recruiting 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lamivudine And Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Lamivudine And Tenofovir Disoproxil Fumarate
Sponsor Trials
Gilead Sciences 16
National Institute of Allergy and Infectious Diseases (NIAID) 14
GlaxoSmithKline 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lamivudine And Tenofovir Disoproxil Fumarate
Sponsor Trials
Other 68
Industry 37
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chubb
Express Scripts
Johnson and Johnson
Daiichi Sankyo
Fuji
Merck
US Army
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.